Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy

Abstract

Most cardiotoxicity after anthracycline-containing therapy occurs within the first year and is associated with anthracycline dose and LVEF at the end of treatment. Early detection and prompt therapy of cardiotoxicity appear crucial for substantial recovery of cardiac function.